Methylphenidate HCl: therapy for attention deficit hyperactivity disorder

@article{Capp2005MethylphenidateHT,
  title={Methylphenidate HCl: therapy for attention deficit hyperactivity disorder},
  author={Philip K Capp and Phillip L. Pearl and Charles Conlon},
  journal={Expert Review of Neurotherapeutics},
  year={2005},
  volume={5},
  pages={325 - 331}
}
Methylphenidate is a first-line therapy for attention deficit hyperactivity disorder, the most prevalent neuropsychiatric disorder of childhood. The compound is a piperidine and the D-threo-isomer is considered the biologically active form. The compound is available in multiple short- and long-acting preparations, having different delivery systems leading to varying kinetics without clear superiority in efficacy or tolerability at the group level. Common adverse effects are insomnia, appetite… Expand
Methylphenidate-induced psychosis in a young antipsychotic-naïve female patient
TLDR
A case report of MPD-induced psychosis in a 31-year-old, antipsychotic-naïve patient is presented and careful evaluation is recommended each time MPD treatment is initiated. Expand
Methylphenidate for attention problems in epilepsy patients: Safety and efficacy
TLDR
Small single-dose and open-label studies suggest efficacy of MPH in adults with epilepsy-related attention deficits, but large, randomized, placebo-controlled, double-blinded studies are needed. Expand
Effects of Once-Daily Oral and Transdermal Methylphenidate on Sleep Behavior of Children With ADHD
TLDR
Little evidence is found that methylphenidate treatment (at least in sustained-release forms) was a significant cause of sleep problems in treated children who were carefully titrated to an optimal dose. Expand
Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects
  • R. Dinis-Oliveira
  • Chemistry, Medicine
  • European Journal of Drug Metabolism and Pharmacokinetics
  • 2016
TLDR
It is expected that knowing the metabolomics of MPH may provide further insights regarding individual contribution for MPH pharmacodynamics and toxicological effects, namely if ethanol is co-consumed. Expand
Methylphenidate Exposure Induces Dopamine Neuron Loss and Activation of Microglia in the Basal Ganglia of Mice
TLDR
It is suggested that chronic MPH usage in mice at doses spanning the therapeutic range in humans, especially at prolonged higher doses, has long-term neurodegenerative consequences. Expand
Methylphenidate Enhances NMDA-Receptor Response in Medial Prefrontal Cortex via Sigma-1 Receptor: A Novel Mechanism for Methylphenidate Action
TLDR
It is demonstrated for the first time that MPH facilitates NMDA-receptor mediated synaptic transmission via σ1 receptor, and such facilitation requires PLC/IP3/PKC signaling pathway, which possibly explains the underlying mechanism for MPH induced addictive potential and other psychiatric side effects. Expand
Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy.
TLDR
Analysis of tic episodes per patient in this study found no correlation between an OROS MPH dose and the frequency of tics, suggesting that MPH-based therapy does not significantly induce or exacerbate tics in children with ADHD. Expand
A Review of the Pathophysiology, Etiology, and Treatment of Attention-Deficit Hyperactivity Disorder (ADHD)
TLDR
This review focuses on the pathophysiology, etiology, and treatment of ADHD and details the adverse effects and drug interaction profiles of the drugs used to treat it. Expand
Effect of Methylphenidate on Sleep Parameters in Children with ADHD
TLDR
Investigation of the acute impact of methylphenidate on sleep parameters in attention-deficit/hyperactivity disorder (ADHD) children found MPH had negative impacts on sleep among young ADHD children, but different preparations and doses did not affect the result. Expand
Chapter 8 – Central Nervous System Stimulants
TLDR
This chapter describes the syntheses of CNS stimulants that are included in the list of Top 200 Drugs by sales for the 2010s, and explains their different chemical structures and pharmacological mechanisms. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 61 REFERENCES
Advances in the Pharmacotherapy of Attention‐Deficit‐Hyperactivity Disorder: Focus on Methylphenidate Formulations
The psychostimulant dl‐methylphenidate (MPH) remains the most common drug therapy in child and adolescent psychiatry for the treatment of attention‐deficit‐hyperactivity disorder (ADHD). Evidence ofExpand
Effects of methylphenidate, desipramine, and l-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder
TLDR
It is suggested that the effects of MPH on attention are due to a combination of noradrenergic and dopaminergic mechanisms, and improved inhibition under DMI could be serotonergically mediated. Expand
Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation.
TLDR
Stimulant medication within this therapeutic range, therefore, results in few, generally mild side effects, and Surprisingly, a high frequency of these behavior side effects were reported during the placebo condition. Expand
Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder.
TLDR
In this double-blind, crossover trial, bupropion and methylphenidate were both effective and did not differ in their overall efficacy as treatments for ADHD. Expand
Use of methylphenidate in a patient with glaucoma and attention-deficit hyperactivity disorder: a clinical dilemma.
TLDR
When used cautiously in conjunction with glaucoma medications and regular ophthalmologic monitoring, methylphenidate and other psychostimulants may be safe in patients with well-controlled, open-angle glau coma. Expand
Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.
TLDR
Many symptoms commonly attributed to stimulant medication are actually preexisting characteristics of children with ADHD and improve with stimulant treatment. Expand
Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder
Atomoxetine (Strattera™, Eli Lilly & Co.) is a selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention-deficit/hyperactivity disorder (ADHD). So far,Expand
Use of Methylphenidate for Attention-Deficit Hyperactivity Disorder in Patients With Epilepsy or Electroencephalographic Abnormalities
TLDR
Methylphenidate is safe and effective in children with ADHD and concomitant active seizures or EEG abnormalities and had a beneficial effect on EEG. Expand
Serum and brain concentrations of methylphenidate: implications for use and abuse
TLDR
The pharmacokinetic properties of MPH in serum (and in brain) that differ for oral and intravenous routes of administration and the importance of acute tolerance in determining pharmacodynamic effects in clinical use and illegal abuse are discussed. Expand
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
TLDR
In children with ADHD-CT, the most common subtype of ADHD, increasing doses of stimulant medication were associated with increased improvement of inattention and hyperactivity symptoms and less benefit was derived from higher doses. Expand
...
1
2
3
4
5
...